Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Resectable Stage II-IIIA NSCLC
NCT04371796Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2020
- Primary completion
- Jun 2021
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Major Pathologic Response Rate. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04371796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371796.